Qure.ai
NativeAI NativePrivateUpdated November 15, 2026AI medical imaging company whose deep learning models interpret chest X-rays and CT scans at scale, deployed across 100+ countries for...
- Website
- qure.ai
- Founded
- 2016
- CEO
- Prashant Warier
- HQ
- Mumbai, India
- Stage
- Private
- Revenue
- Not disclosed
- Total Funding
- $157M
- Employees
- 201-500
Executive Summary
Updated Nov 15, 2026
What they do
- Deep learning models that read chest X-rays, head CTs and chest CTs
- Lung nodule detection and follow-up management suite for early lung cancer detection
- Triage and notification software for stroke, brain bleeds and trauma on head CT
Why it matters
- Says it has 26 FDA-cleared indications and deployments in 4,000+ hospitals worldwide
- Microsoft Precision Imaging Network integration makes its lung cancer suite easier to deploy in the US
- Large public-health programs in TB, lung cancer and pandemic readiness show it works at population scale
Best fit
- Health systems running lung cancer screening or incidental nodule follow-up programs
- Emergency departments and teleradiology groups that need fast chest X-ray and head CT triage
- Ministries of health, NGOs and pharma running TB or lung screening at scale
Watch-outs
- Net losses reportedly widened to about ₹90 crore in FY25 despite revenue growth
- US commercial presence is still being built, and its North America sales leadership is new
- Clearances are spread across many narrow indications, so check the scope of each one
Products & Offerings
qXR
Chest X-ray AI that detects and localizes many findings, including nodules, TB, pneumothorax and tube placement, through its FDA-cleared qXR-Detect and related modules.
qER
FDA-cleared head CT triage software that flags intracranial bleeds, mass effect, midline shift and fractures for urgent review.
Lung Cancer Detection and Management Suite (qXR-LN, qCT)
Software that detects nodules on X-ray and CT and tracks patients through follow-up care, and is available through Microsoft's Precision Imaging Network.
Aira
AI clinical decision support system that has received Class IIb CE certification in Europe.
QureOS
AI-powered digital health operating system that helps health systems in low- and middle-income countries run screening and care pathways.
Latest News
Fortune India · 14 days ago
PositivePR Newswire · 2 months ago
PositiveUpdated Nov 15, 2026
Qure.ai is one of the most widely deployed imaging AI vendors and has an unusually broad set of FDA clearances for chest X-ray. Health systems buying AI for chest X-ray, lung nodules or head CT triage should put it on the shortlist next to rivals such as Aidoc, Lunit and Annalise.ai. In due diligence, check its US support capacity, how it integrates with your PACS, and whether it has the funding to stay viable as losses grow.
Signal Provenance
Latest observation date and source for each signal category
| Signal Category | Last Updated | Source |
|---|---|---|
Funding Signals Last funding round, Funding stage | Nov 10, 2026 | Cited web research |
Hiring Velocity Headcount, Headcount growth | Nov 15, 2026 | Research agents (estimate) |
Technical Output Research papers, GitHub activity | Nov 9, 2026 | Hugging Face Hub + news feed + research agents |
News Sentiment News mentions, News sentiment | Nov 15, 2026 | Verified news feed |
Partnership Signals Enterprise partnerships, Distribution partners | Nov 15, 2026 | Research agents (estimate) |
Revenue Indicators ARR estimate, Revenue growth | Nov 15, 2026 | Research agents (estimate) |
Leadership Signals CEO tenure, Founder-led | Nov 15, 2026 | Research agents (estimate) |
Competitive Position Category rank, Market share | Nov 15, 2026 | Research agents (estimate) |
Why this Bluescore?
6 dimensions, each scored 0–10 against all 250 companies. Each adds its weight × score to the Bluescore — see methodology
Qure.ai's Bluescore of 50.8 rests most on Data & Model Moat (6.8, top 11%) and Business Model & Revenue (4.9, 66th percentile). Its weakest area is Investment Momentum (3.8, 34th percentile).
In plain English
Qure.ai ranks #95 of 247 with a Bluescore of 50.8 out of 100, lifted mainly by Data & Model Moat, where its score of 6.8 of 10 adds 12.9 of 19 points and sits at the 89th percentile among the AI250. Talent & Research (3.7 of 10, 47th percentile) and Investment Momentum (3.8 of 10, 34th percentile) hold it back, with Investment Momentum adding just 3.8 of 10 points. The biggest opportunity is Business Model & Revenue, a 21% weight where a score of 4.9 of 10 leaves 10.8 points on the table, the most of any dimension.
Written by AI from the scores below and checked against them; updated nightly.
Risks
Updated Nov 15, 2026